{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:08Z","timestamp":1787063108895,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP B53C22004000006"],"award-info":[{"award-number":["CUP B53C22004000006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.prp.2024.155415","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:22:30Z","timestamp":1719602550000},"page":"155415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients"],"prefix":"10.1016","volume":"260","author":[{"given":"Andrea","family":"Botticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"d'Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cira","family":"Di Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Della Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Carletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalinda","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Polimeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Vincentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"di Cristofano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Messineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Leopizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Cerbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.prp.2024.155415_bib1","first-page":"11383","article-title":"Cetuximab plus chemotherapy versus chemotherapy alone in recurrent or metastatic head and neck squamous cell carcinoma: a cost-effectiveness analysis","volume":"6","author":"Yitian","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.prp.2024.155415_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.prp.2024.155415_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.prp.2024.155415_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103041","article-title":"The 5\u2013Ws of immunotherapy in head and neck cancer","volume":"153","author":"Botticelli","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"10212","key":"10.1016\/j.prp.2024.155415_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.prp.2024.155415_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jpm11070651","article-title":"The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study","volume":"11","author":"Botticelli","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.prp.2024.155415_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2024.155415_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.prp.2024.155415_bib9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2326-6066.CIR-14-0075","article-title":"Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists","volume":"2","author":"Sitkovsky","year":"2014","journal-title":"Cancer Immunol. Res"},{"issue":"15","key":"10.1016\/j.prp.2024.155415_bib10","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-16-0544","article-title":"Adenosine 2B receptor expression on cancer cells promotes metastasis","volume":"76","author":"Mittal","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155415_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12528","article-title":"The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets","volume":"276","author":"Allard","year":"2017","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.prp.2024.155415_bib12","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155415_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2024.155415_bib14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10585-007-9081-y","article-title":"RNA interference of ecto-5\u2032-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion","volume":"24","author":"Zhi","year":"2007","journal-title":"Clin. Exp. Metastas-.-."},{"issue":"8","key":"10.1016\/j.prp.2024.155415_bib15","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.4049\/jimmunol.1301274","article-title":"Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells","volume":"191","author":"Terp","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2024.155415_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12885-018-4073-7","article-title":"Comprehensive evaluation of NT5E\/CD73 expression and its prognostic significance in distinct types of cancers","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.prp.2024.155415_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00428-019-02722-6","article-title":"CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer","volume":"476","author":"Cerbelli","year":"2020","journal-title":"Virchows Arch."},{"issue":"27","key":"10.1016\/j.prp.2024.155415_bib18","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1073\/pnas.1222251110","article-title":"CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer","volume":"110","author":"Loi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.prp.2024.155415_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/his.14562","article-title":"Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study","volume":"80","author":"Cerbelli","year":"2022","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.prp.2024.155415_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.prp.2024.155415_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/cancers13020177","article-title":"CD73, tumor plasticity and immune evasion in solid cancers","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.prp.2024.155415_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/19420862.2016.1143182","article-title":"Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non- competitive mechanism of action","volume":"8","author":"Geoghegan","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.prp.2024.155415_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4123","article-title":"Safety, efficacy and pharmacodynamics (pd) of medi9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (crc) or pancreatic cancer (panc)","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2024.155415_bib24","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.prp.2024.155415_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3051907","article-title":"Head and neck squamous cell carcinoma: NT5E could be a prognostic biomarker","volume":"2022","author":"Zhang","year":"2022","journal-title":"Appl. Bionics Biomech."},{"issue":"38","key":"10.1016\/j.prp.2024.155415_bib26","doi-asserted-by":"crossref","first-page":"61690","DOI":"10.18632\/oncotarget.11435","article-title":"CD73 is associated with poor prognosis in HNSCC","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155415_bib27","author":"Yaoting Zhang","year":"2022","journal-title":"Cancer facts Fig. 2021 - Am. Cancer Soc. 2021"},{"issue":"42","key":"10.1016\/j.prp.2024.155415_bib28","doi-asserted-by":"crossref","first-page":"26659","DOI":"10.18632\/oncotarget.25426","article-title":"CD73 expression and clinical significance in human metastatic melanoma","volume":"9","author":"Monteiro","year":"2018","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.prp.2024.155415_bib29","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","article-title":"CD73 is associated with poor prognosis in high-grade serous ovarian cancer","volume":"75","author":"Turcotte","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.prp.2024.155415_bib30","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/annonc\/mdx730","article-title":"Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial","volume":"29","author":"Buisseret","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2024.155415_bib31","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/cancers12092648","article-title":"Tissue immune profile: a tool to predict response to neoadjuvant therapy in triple negative breast cancer","volume":"12","author":"Cerbelli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.prp.2024.155415_bib32","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.2174\/0929867325666180117101114","article-title":"Role of CD73 in disease: promising prognostic indicator and therapeutic target","volume":"25","author":"Yang","year":"2018","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.prp.2024.155415_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.969034","article-title":"Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma","volume":"13","author":"Shen","year":"2022","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.prp.2024.155415_bib34","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/ijc.31534","article-title":"Specific blockade CD73 alters the \"exhausted\" phenotype of T cells in head and neck squamous cell carcinoma","volume":"143","author":"Deng","year":"2018","journal-title":"Int J. Cancer"},{"issue":"5","key":"10.1016\/j.prp.2024.155415_bib35","article-title":"CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment","volume":"11","author":"Lu","year":"2022","journal-title":"J. Extra Vesicles"},{"issue":"1","key":"10.1016\/j.prp.2024.155415_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","article-title":"CD73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824003261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824003261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T14:21:38Z","timestamp":1735136498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824003261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":36,"alternative-id":["S0344033824003261"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155415","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155415","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155415"}}